Myomo, Inc., a commercial stage medical robotics Company, today announced a Regulation A+ initial public offering that allows any investor the opportunity to invest in the Company’s vision for expanded mobility for those suffering from neurological disorders and upper limb paralysis. Myomo’s non-invasive technology, exclusively licensed from Massachusetts Institute of Technology, restores a patient’s ability to use their partially paralyzed or weakened arms and hands again so that they can return to work, live independently and reduce their cost of care.
